Following genotoxic stress,
Introduction
p53 is a key tumor suppressor that is mutated in > 50% of human cancers [1 -3] . p53 is a transcription factor that activates the transcription of its target genes by binding to a p53 DNA-binding consensus sequence [2] . Importantly, proteins encoded by p53 target genes contribute to the determination of cell fate after genotoxic stress [4, 5] . p53 mediates its tumor-suppressive functions by inducing cell growth arrest, apoptosis, or senescence [3, 6] .
A recent study [7] has identified a potential p53 DNA-binding site about 3.7 kb upstream in the promoter region of the human Notch1 gene. Notch1 gene encodes a protein that belongs to a family of large (f 300 kDa), single-pass, evolutionarily conserved membrane-associated receptors [8, 9] . Other members of the mammalian Notch family include Notch2, Notch3, and Notch4. Proteins in the family primarily regulate cell fate and lineage specification during embryonic and postembryonic development. These proteins have conserved structural elements in their extracellular transmembrane and intracellular domains [8, 9] . Mammalian cells are shown to express five ligands (i.e., Jagged-1, Jagged-2, Delta-1, Delta-3, and Delta-4) for Notch family receptors [10] . Notch signaling is initiated by receptor -ligand interactions between neighboring cells, resulting in two successive proteolytic cleavages by tumor necrosis factor-a -converting enzyme and gamma secretase/ presenilin complex [11, 12] . These two proteolytic cleavages of the Notch receptor protein result in the release of the intracellular domain [notch intracellular domain (NIC), the functionally active form of Notch], which translocates to the nucleus and modulates the transcription of target genes. Gamma secretase inhibitors (GSIs), such as the tripeptide inhibitor z-Leu -Leu -Nle -CHO, inhibit the generation of NIC [13, 14] . Consequently, treatment of cells with GSI is shown to inhibit Notch signaling [13, 15] and to decrease cell survival.
After nuclear translocation, NIC binds to CBF1 (also termed RBP-Jn), a DNA-binding protein [16, 17] . In the absence of NIC, CBF1 acts as a transcriptional repressor. However, the binding of NIC to CBF1 converts it to a transcriptional activator, which results in Notch1-dependent transcriptional activation of genes. Notch1 target genes include Hes (Hairy/Enhancer of Split), p21 CIP1/WAF1 , and cyclin D [16, 17] .
Similar to its role in development, the role of Notch family members in oncogenesis appears to be cell type/organspecific. Aberrant Notch1 signaling has been cited as causative in T-cell lymphoblastic leukemias, certain lymphomas, breast carcinomas, and kidney carcinomas [18] . In keratinocytes, however, Notch1 signaling mediates terminal differentiation [16] . Neoplastic effects of Notch1 may be attributed to its role as a cell survival factor in tumor cells mainly through the inhibition of p53 through mammalian target of rapamycin (mTOR) [19] . In addition, there have been other reports of Notch-mediated inhibition of p53 functions, including apoptosis [20, 21] .
Although the role of Notch1 in regulating p53 function has been reported, it is not known whether p53 has any effect on Notch1 expression and/or its functions. In the present study, we demonstrate that the restoration of p53 function in human cancer cell lines deficient in p53 function upregulates the expression of Notch1. Significantly, we found that genotoxic stress, which resulted in transcriptional activation of p53, also upregulated the expression of Notch1 in human cancer cell lines. Moreover, inhibition of Notch1 activity after genotoxic stress by an inhibitor of Notch signaling increased susceptibility to apoptosis. Together, our observations provide support for the idea that induction of Notch1 expression by p53 in cells counteracts p53-mediated proapoptotic functions.
Materials and Methods

Cell Lines, Culture Conditions, and Treatments
Saos-2 cells, stably expressing the temperature-sensitive mutant (Val138 mutation) of human p53 (with Arg72) [22] , were generously provided by Dr. Maureen Murphy (Fox Chase Cancer Center, Philadelphia, PA). LNCaP, DU-145, PC-3, MCF-7, and Saos-2 cell lines were purchased from the American Type Culture Collection (Manassas, VA). All cell lines (except Saos-2) used in the study were maintained in (high-glucose) Dulbecco's modified Eagle's medium (Invitrogen Life Technologies, Carlsbad, CA) supplemented with 10% (vol/vol) fetal bovine serum and antibiotics. The Saos-2 cell line was maintained in RPMI 1640 medium.
Temperature-sensitive cells were maintained at the specified temperature, and the medium was left unchanged for the duration (15-17 hours) of treatment. Etoposide (Calbiochem, San Diego, CA) was prepared as a 50-mM stock solution in dimethyl sulfoxide (DMSO) and stored at À20jC until use. Control cell plates were treated with an equal volume of DMSO.
Knockdown of p53 Expression
Subconfluent cultures of LNCaP cells were transfected with a pool of p53 siRNA (cat no. M-003557-00-05; purchased from Dharmacon, Denver, CO) or nonspecific control siRNA (cat no. D-001206-02-05) as recommended by the supplier using Lipofectamine (Invitrogen Life Technologies) transfection agent. Sixty hours after the transfection of cells, cell lysates were prepared and processed for immunoblotting.
Nucleofection
PC-3 or Saos-2 cells were nucleofected with pCMV or pCMV-p53 plasmid (2 mg) using Nucleofector-II device (Amaxa Biosystems, Nattermannallee 1, Germany). PC-3 cells were nucleofected using Nucleofection Kit VCA-1001 (Amaxa Biosystems) and the T-013 program, as suggested by the supplier. For Saos-2 cells, we used the same nucleofection kit with the program D-024. If so indicated, 24 hours after the nucleofection of cells, cells were treated with etoposide (45 mM) for 24 hours. Forty-eight hours after nucleofection, cells were processed for immunoblotting.
Reverse Transcription -Polymerase Chain Reaction
Total RNA was isolated from the indicated cells using TRIzol reagent (Invitrogen Life Technologies), as suggested by the supplier. Isolated total RNA was subjected to cDNA synthesis using SuperScript First-Stand Synthesis system (Invitrogen Life Technologies), as suggested by the supplier, followed by PCR, using a pair of primers specific to human Notch1 cDNA (forward primer: 5V-CAGGCAATCCGAG-GACTATG-3V; reverse primer: 5V-CAGGCGTGTTGTTCT-CACAG-3V), p21, or actin cDNA using a kit from Invitrogen Life Technologies, as suggested by the supplier. The PCR product for human Notch1 (428 bp) was analyzed by agarose gel electrophoresis after 36 PCR cycles.
Immunoblotting and Antibodies
Total cell lysates were prepared in a modified RIPA buffer (50 mM Tris -HCl pH 8.0, 250 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate plus complete mini EDTA-free protease inhibitor cocktail; Roche, Mannheim, Germany). Lysates were incubated for 30 minutes on ice and sonicated briefly. The lysates were centrifuged at 14,000 rpm in a microfuge at 4jC for 10 minutes, and equivalent protein amounts were subjected to immunoblotting as described previously [23] .
The following antibodies used in our experiments were purchased from Santa Cruz Biotechnology (Santa Cruz, CA): p53 (horseradish peroxidase -conjugated; cat no. sc-6243), p21 (horseradish peroxidase -conjugated; no. sc-397), Notch2 (no. sc-5545), Notch4 (no. sc-5594), glyceraldehyde-3-phosphatase dehydrogenase (GAPDH) (no. sc-32233), and a-tubulin (no. sc-8035). Human total Notch1 antibody (bTan20 ascites fluid) was purchased from Developmental Studies Hybridoma Bank (Iowa City, IA). Processed/cleaved Notch1 antibody (Val1744; no. 2421) was purchased from Cell Signaling Technology (Danvers, MA). b-Actin antibody (no. A3853) was from Sigma (St. Louis, MO).
Reporter Assays
Subconfluent cultures (in 60-mm plates) of cells were transfected with FuGene6 transfection agent (Roche Applied Science, Indianapolis, IN), as suggested by the supplier, using 2 mg of total plasmid DNA per plate. Forty-two to 44 hours after transfection, cells were lysed, and the activities of firefly luciferase and Renilla luciferase were determined as described previously [24] .
Flow Cytometry
Flow cytometry was performed on single-cell suspensions on adherent (after trypsin and EDTA treatment) and floating cells after pooling them. Briefly, for cell cycle analysis, cells were stained with propidium iodide (50 mg/ml; Sigma) and subjected to flow cytometry using a Coulter Epics XL-MCL flow cytometer (Coulter, Fullerton, CA), as described previously [24] . Apoptosis was measured by the accumulation of cells with sub-G 0 DNA content.
Results
Recently, Notch1 gene has been identified as a potential transcriptional target of p53 in human cells [7] . Therefore, we tested whether p53 could regulate the expression of Notch1 gene in human cancer cell lines that are deficient in p53 function.
Expression of a Temperature-Sensitive Mutant of p53 in Human Saos-2 Cells Upregulates the Expression of Notch1
To determine whether p53 could upregulate the expression of Notch1 in human cancer cells, we chose to use the well-characterized human osteosarcoma Saos-2 cell system (Saos-2 cells are null for p53). Saos-2 cells express a temperature-sensitive mutant of p53 with the amino acid residue Arg (instead of Pro) at position 72 (cells indicated as Saos Arg72 ; see Dumont et al. [22] ). As shown in Figure 1A , incubation of Saos Arg72 cells at 32jC for 16 or 24 hours resulted in upregulation of p21 protein, a transcriptional target of p53 protein. Importantly, levels of Notch1 protein also increased several fold in extracts from Saos Arg72 cells that were incubated at 32jC.
To rule out the possibility that incubation of cells at a reduced (32jC) temperature could account for increases in Notch1 protein levels (independent of p53 expression), we also compared Notch1 protein levels between parental Saos-2 cells that were incubated at 39j and parental Saos-2 cells that were incubated at 32jC. We found no difference between Notch1 protein levels in extracts from cells incubated at these two temperatures (data not shown). . Sixty hours after the nucleofection of cells, cells were lysed, and cell lysates containing an equal amount of proteins were processed for immunoblotting using antibodies specific to the indicated proteins. (C) Subconfluent cultures of Saos Arg72 cells were incubated either at 39jC (lane 1) or at 32jC (lane 2). Twenty-four hours after incubation, total RNA was isolated, and steady-state levels of Notch1, p21, and actin mRNA were analyzed by semiquantitative reverse transcription -polymerase chain reaction. (D and E) Two sets of Saos Arg72 cell cultures (in 60-mm plates) were transfected with p21-luc, CBF1-luc, or Hes1-luc reporter plasmid (1.8 g) along with pRL-TK plasmid (0.2 g; plasmids in a 9:1 ratio) using FuGene6 transfection reagent. One set of plates for each reporter was incubated at 39jC, and the other sets of plates were incubated at 32jC. Forty-four hours after incubation, cells were processed for dual luciferase reporter activity assays, as described in Materials and Methods. Firefly luciferase reporter activity was normalized to Renilla luciferase activity to control for variations in nucleofection efficiencies. Luciferase activity for p21-luc (C) and for CBF1-luc and Hes1-luc (D) in control cells is shown.
Moreover, forced expression of wild-type p53 in Saos-2 cells (after the nucleofection of cells with pCMV-p53 plasmid encoding wild-type p53) also resulted in upregulation of Notch1 expression ( Figure 1B) .
We also noted that steady-state levels of Notch1 mRNA also increased about two-fold in Saos Arg72 cells after their incubation at 32jC for 24 hours ( Figure 1C ). Although we were unable to detect the processed NIC form of Notch1 protein in extracts from Saos Arg72 cells that were incubated at 32jC for 16 or 24 hours using Val1744 antibody to cleaved Notch1 protein, we found that the activity of the two Notch1responsive reporters (CBF1-luc and Hes1-luc) was consistently stimulated in Saos Arg72 cells after incubation at 32jC for 24 hours (Figure 1, D and E ) . Moreover, we noted that the activity of CBF1-luc reporter was stimulated robustly compared to the activity of Hes1-luc reporter. The reasons for this differential stimulation of Notch1-responsive reporters in Saos Arg72 cells remain unknown. Together, these observations suggested that the restoration of p53 function in Saos-2 cells upregulated Notch1 expression and stimulation of the activity of Notch1-responsive reporters.
The Functional Status of p53 in Human Cancer Cell Lines Correlated with Expression Levels of Notch1 Protein
Our observations on the upregulation of Notch1 expression by functional p53 in human Saos-2 cell lines made it important to determine whether the functional status of p53 in human cancer cell lines correlates with expression levels of Notch1. Because three common human prostate cancer cell lines (LNCaP, DU-145, and PC-3) and two human breast cancer cell lines (MCF-7 and MDA-468) are known to differ with respect to the functional status of p53, we compared the expression levels of Notch1 protein in these cancer cell lines. Consistent with a previous report [25] , expression of p53 was detectable in LNCaP (wild-type p53) and DU-145 (mutant p53) cells (Figure 2A ). However, the expression of p53 was not detectable in PC-3 cells (null for p53). Likewise, the expression of p53 was detectable in MCF-7 (wild-type p53) and MDA-468 (mutant p53) cells ( Figure 2B ). Moreover, consistent with the functional status of p53 in these cell lines, expression levels of p21 were relatively high in extracts from LNCaP and MCF-7 cells. Importantly, consistent with a previous report [26] , levels of the full-length Notch1 protein were also relatively high in LNCaP cells than in DU-145 and PC-3 cells (cf. lane 1 with lane 2 or lane 3). Similarly, levels of Notch1 protein were relatively higher in MCF-7 cells than in MDA-468 cells. Together, these observations suggested that the wild-type status of p53 in the above human cancer cell lines is associated with increased expression levels of Notch1 protein.
Forced Expression of p53 in PC-3 Cells Upregulated Notch1 Expression
Because PC-3 cells are null for p53, we tested whether restoration of p53 expression in these cells and activation of p53 by genotoxic stress have any effect on Notch1 expression. As shown in Figure 2C , restoration of the expression of wild-type p53 in cells upregulated p21 and Notch1 protein levels (cf. lane 3 with lane 1). Interestingly, treatment of these cells expressing wild-type p53 with etoposide further upregulated the expression of both p21 and Notch1 proteins (cf. lane 4 with lane 3). These observations suggested that restoration of p53 function in PC-3 cells upregulated Notch1 expression.
Knockdown of p53 Expression in LNCaP Cells Downregulated Notch1 Expression
To further examine whether p53 regulates the expression of Notch1, we chose to knock down the expression of p53 in LNCaP cells. As shown in Figure 2D , transfection of LNCaP cells with a pool of p53 siRNA, but not control siRNA, resulted in a > 70% decrease in p53 protein levels (cf. lane 2 with lane 1). Importantly, the knockdown of p53 expression in cells resulted in decreases in p21 and Notch1 protein levels. These observations suggested that the expression of functional p53 in LNCaP cells contributes to relatively higher steady-state levels of Notch1 protein.
Activation of p53 By Genotoxic Stress Upregulates Notch1 Expression
Genotoxic stress to cells due to their exposure to DNAdamaging agents, such as etoposide, is known to activate p53-mediated transcription of its target genes [27] . Therefore, we sought to determine whether exposure of LNCaP or MCF-7 cell lines, which express wild-type p53, to etoposide results in upregulation of Notch1. As shown in Figure 3A , treatment of LNCaP cells with etoposide resulted in the upregulation and activation of p53 in a dose-dependent manner. Moreover, treatment of cells resulted in upregulation of p21 and Notch1 proteins. Similarly, treatment of MCF-7 cells with etoposide resulted in upregulation of both p21 and Notch1 protein levels ( Figure 3B ). However, treatment of human prostate cancer cell lines PC-3 (null for p53) and DU-145 (mutant p53) with increasing concentrations (22.5, 45 , or 90 mM) of etoposide for 24 hours did not result in upregulation of Notch1 protein (Figure 3 , C and D, respectively). Together, these observations indicated that genotoxic stress -induced activation of p53 in human cancer cell lines also upregulates Notch1 expression.
p53 Differentially Regulates the Expression of Notch Family Members
p53-mediated upregulation of Notch1 mRNA and protein in Saos-2 cells (Figure 1 ) made it interesting to determine whether p53 also regulates the expression of other members of the Notch receptor family. For this purpose, we compared the expression levels of Notch1, Notch2, and Notch4 proteins in extracts from Saos Arg72 cells that were incubated at 39j or 32j. Consistent with our previous observations ( Figure 1A) , we found that incubation of cells at 32jC resulted in upregulation of Notch1 proteins (Figure 4 ; cf. lane 2 with lane 1). Interestingly, incubation of cells at 32jC did not result in upregulation of Notch2 or Notch4 protein 2 with lane 1) . These observations suggested that functional p53 differentially regulates the expression of Notch receptor family members in human Saos Arg72 cells.
Inhibition of Notch1 Activity and Genotoxic Stress Cooperate in MCF7 Cells to Increase Susceptibility to Apoptosis
Notch signaling is known to play an important role in mammary gland tumorigenesis [28] . Moreover, increased expression of Notch1 protein in human breast cancer cell lines is associated with their resistance to apoptosis [29] . Therefore, we tested whether genotoxic stress -induced upregulation of Notch1 expression in the MCF-7 breast cancer cell line contributes to increases in resistance to apoptosis. As shown in Figure 5 , treatment of MCF-7 cells with GSI (an inhibitor of Notch1 activity) [13, 15] or etoposide resulted in increases in p53, p21, and Notch1 protein levels. Consistent with increases in p53 protein levels after GSI treatment of cells, we noted some cleavage of PARP protein, an indication of apoptosis. However, flow cytometry analysis of GSI-treated cells (after propidium iodide staining of DNA) for the accumulation of cells in sub-G 0 phase indicated no increase in sub-G 0 cells (compared to control cells; Figure 5B) . Moreover, treatment of cells with etoposide alone did not result in detectable cleavage of PARP protein.
Interestingly, treatment of cells with both GSI and etoposide resulted in measurable increases in the cleavage of PARP protein (cf. lane 4 with lane 2) and measurably increased accumulation of cells in the sub-G 0 phase, as determined by flow cytometry ( Figure 5B ). These observations indicated that inhibition of Notch1 activation in MCF-7 cells and etoposide treatment of cells together increase susceptibility to apoptosis.
Discussion
Inhibition of cell proliferation by p53 is largely attributable to its ability to transcriptionally activate the expression of genes that encode proteins, which determine cell fate [4, 30] . Depending on cellular context, wild-type p53 limits cell proliferation in response to DNA damage and other cellular stresses by inducing cell cycle arrest, apoptosis, or senescence [2] [3] [4] [5] .
The human Notch1 gene has been identified as a direct transcriptional target of p53 [7] . Based on this observation and accumulating evidence for crosstalks between Notch1 and p53 signaling pathways to regulate cell fate [20, 21] , we investigated whether p53 could regulate Notch1 gene expression in human cancer cell lines that lack p53 function. Our experiments revealed that: 1) expression of functional p53 in human cancer cell lines upregulated the expression of Notch1 mRNA and protein (Figure 1) ; 2) p53-mediated increased levels of Notch1 protein in cell lines stimulated the activity of Notch-responsive reporters (Figure 1) ; 3) knockdown of p53 expression in LNCaP cells reduced the expression levels of Notch1 protein (Figure 2) ; 4) in response to genotoxic stress by etoposide treatment of human prostate (LNCaP) and breast (MCF-7) cancer cell lines, transcriptional activation of p53 also upregulated Notch1 expression ( Figure 3) ; 5) p53 did not upregulate the expression of Notch2 and Notch4 in Saos-2 cells ( Figure 4 ); and 6) treatment of MCF-7 cells with GSI, an inhibitor of Notch signaling, increased susceptibility to apoptosis induced by etoposide treatment of cells ( Figure 5 ). Together, these observations provide support for the idea that p53-mediated upregulation of Notch1 expression in human cancer cell lines counteracts p53-mediated proapoptotic functions.
Consistent with our observations, activated Notch1 is shown to exert antiapoptotic effects on cells by inhibiting p53-mediated transactivation [20] . Moreover, survival signaling by Notch1 is mediated, in part, through the PI3 kinase/ AKT/mTOR axis [19] . In contrast to the antiapoptotic role of activated Notch1 in the above cell systems, conditional expression of a constitutively active form of Notch1 in early progenitor cells, but not in postmitotic neurons, selectively induced apoptosis [31] . Together, these observations provide support for the idea that Notch1-mediated determination of cell fate depends on cellular context. p53 has been reported to negatively regulate Notch1 expression and activation in several mouse thymoma cell lines [21] . Moreover, the study also showed that expression of activated Notch1 (NIC) was elevated in Trp53 À/À thymocytes compared to that in Trp53 +/+ thymocytes. Because activated p53 is shown to differently activate the transcription of genes in different tissues in vivo [32] , further work will be needed to determine whether p53-mediated regulation of Notch1 expression varies among different mouse and human tissues and cell lines derived from these tissues.
It has been reported that SV40 virus -encoded proteins (large T antigen and small t antigen) that inactivate p53 function can upregulate the expression of Notch1 mRNA and protein in human mesothelial cells [33] . Therefore, it is likely that signaling pathways independent of p53 also activate the transcription of Notch1 gene in SV40 virus -infected mesothelial cells. Furthermore, it is important to note that p53 knockout mice are viable with no obvious developmental abnormalities [34] . However, these mice are prone to developing certain types of cancers later in life [34] . These observations are consistent with the idea that, in addition to p53, other factors also contribute to the regulation of Notch1 expression in certain mouse and human cells.
While this manuscript was under review, two reports [35, 36] provided evidence that the human Notch1 gene is a direct transcriptional target of p53 tumor suppressor. In one of these studies [35] , the authors identified two potential p53 DNA-binding sites (p53-A and p53-B) in the promoter region (about 3.5 and 0.8 kb, respectively) of Notch1 gene. Moreover, they reported that p53 associated with these p53 DNAbinding sites in chromatin immunoprecipitation assays and upregulated the expression of Notch1 in normal primary human keratinocytes. Similarly, Yugawa et al. [36] reported the presence of at least two (proximal and distal) putative p53 DNA-binding sites in the promoter region of the human Notch1 gene. Importantly, mutations in the distal p53 DNAbinding site resulted in reduction in the basal activity of the promoter and lack of response to ionizing radiation. Moreover, this study also indicated that inactivation of p53 by human papillomavirus -encoded E6 protein in human keratinocytes and epithelial cells resulted in downregulation of Notch1 expression. Therefore, taken together, the observations described here and in the two studies [35, 36] are consistent with the idea that the human Notch1 gene is a transcriptional target of p53 in a variety of human cells. More importantly, these studies provide support for the idea that, depending on cellular context, Notch1 expression contributes to a different cell fate.
Aberrant Notch1 signaling has been cited as causative in T-cell lymphoblastic leukemia, certain lymphomas, breast carcinomas, and kidney carcinomas [18] . Significantly, our observations raise the possibility that Notch1 protein can function as a survival effector in wild-type p53-containing human cancer cells exposed to genotoxic stress. Because many human tumors maintain wild-type p53 status, inhibition of Notch1 function provides a logical approach to selectively targeting such tumors for effective cancer therapy.
